Park Jin-Mo, Seo Incheol, Kang Minsung, Chong Gun Oh, Lee Yoon Hee, Park Jin-Sung
Department of Neurology, Dongguk University College of Medicine, Dongguk University Gyeongju Hospital, Gyeongju 38067, Republic of Korea.
Department of Immunology, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
J Clin Med. 2025 Jun 25;14(13):4485. doi: 10.3390/jcm14134485.
Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating side effect of cancer treatment, which is more common in patients with ovarian cancer who are receiving paclitaxel and carboplatin treatment. Although prior studies have explored the association between obesity and CIPN, most relied on subjective grading systems. This study aims to evaluate the relationship between being overweight and CIPN using the Total Neuropathy Score (TNS), a more objective and comprehensive assessment tool. The purpose of this study is to investigate the relationship between being overweight and the onset and severity of CIPN in a cohort of South Korean patients with ovarian cancer who were treated with paclitaxel and carboplatin. The study was conducted retrospectively at a single tertiary hospital in South Korea from March 2013 to February 2022. Included in this study were forty-two individuals who were diagnosed with epithelial ovarian cancer and who had developed neuropathic symptoms following chemotherapy. Patient characteristics, laboratory findings, and disease-specific TNS were analyzed. Overweight patients showed significantly more severe CIPN, with higher Total Neuropathy Scores (TNS; = 0.019) and earlier symptom onset ( < 0.05) compared to normal-weight patients. Causal mediation analysis also revealed a significant direct effect of BMI on TNS ( = 0.006). However, no significant correlation was found between BMI and TNS using Kendall's rank correlation, and other neuropathic symptoms or laboratory parameters did not show statistically significant group differences. The study suggests that overweight may be associated with the severity and onset of CIPN in patients with ovarian cancer who are receiving paclitaxel and carboplatin chemotherapy. While the results are preliminary, they underscore the importance of addressing this modifiable risk factor in clinical care. Further research is needed to better understand the underlying mechanisms and to inform future therapeutic strategies.
化疗引起的周围神经病变（CIPN）是癌症治疗中一种使人衰弱的副作用，在接受紫杉醇和卡铂治疗的卵巢癌患者中更为常见。尽管先前的研究探讨了肥胖与CIPN之间的关联，但大多数研究依赖主观分级系统。本研究旨在使用总神经病变评分（TNS）评估超重与CIPN之间的关系，TNS是一种更客观、全面的评估工具。本研究的目的是调查在接受紫杉醇和卡铂治疗的韩国卵巢癌患者队列中，超重与CIPN的发生及严重程度之间的关系。该研究于2013年3月至2022年2月在韩国一家单一的三级医院进行回顾性研究。本研究纳入了42名被诊断为上皮性卵巢癌且在化疗后出现神经病变症状的个体。分析了患者特征、实验室检查结果和疾病特异性TNS。与体重正常的患者相比，超重患者的CIPN明显更严重，总神经病变评分更高（TNS；P = 0.019），症状出现更早（P < 0.05）。因果中介分析还显示BMI对TNS有显著直接影响（P = 0.006）。然而，使用肯德尔等级相关性分析发现BMI与TNS之间无显著相关性，其他神经病变症状或实验室参数也未显示出统计学上的显著组间差异。该研究表明，超重可能与接受紫杉醇和卡铂化疗的卵巢癌患者CIPN的严重程度和发生有关。虽然结果是初步的，但它们强调了在临床护理中解决这一可改变的风险因素的重要性。需要进一步研究以更好地理解潜在机制并为未来的治疗策略提供依据。
